Caspase-9 mediates Puma activation in UCN-01-induced apoptosis

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Nie, C ^a   Luo, Y ^a   Zhao, X ^a   Luo, N ^b   Tong, A ^a   Liu, X ^a   Yuan, Z ^a   Wang, C ^a   Wei, Y ^a  

^a SICHUAN UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CASPASE 3; CASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PUMA PROTEIN; TRANSCRIPTION FACTOR FKHRL1; X LINKED INHIBITOR OF APOPTOSIS; 7-HYDROXYSTAUROSPORINE; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; ONCOPROTEIN; PROTEIN BCL X; PROTEIN P53; PUMA PROTEIN, MOUSE; SIGNAL PEPTIDE; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MITOCHONDRION; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; FIBROBLAST; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; TUNEL ASSAY;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE, NUDE; MITOCHONDRIAL PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922434956     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.461     Document Type: Article

References (32)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
2. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
3. Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F et al. Absence of Bcl-xL downregulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007; 105: 31-44.
4. Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A et al. Bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998; 4: 517-524.
5. Yu J,Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 1931-1936.
6. Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 2007; 26: 4189-4198.
7. Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F et al. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 2012; 444: 291-301.
8. Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY et al. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med 2011; 17: 1262-1274.
9. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-1960.
10. Gilliand P. Evolution of family policy in the light of demographic development in West European countries. Int Soc Secur Rev 1989; 42: 395-426.
11. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60: 2108-2112.
12. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKTrelated pathways. Blood 2003; 102: 1824-1832.
13. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004; 10(Part 1): 4029-4037.
14. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1: 913-922.
15. Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 2007; 110: 2092-2101.
16. Bhonde MR, Hanski ML, Magrini R, Moorthy D, Muller A, Sausville EA et al. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 2005; 24: 148-156.
17. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000; 60: 4386-4390.
18. Manns J, Daubrawa M, Driessen S, Paasch F, Hoffmann N, Loffler A et al. Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase- 9 in the absence of Apaf-1. FASEB J 2011; 25: 3250-3261.
19. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-292.
20. Chen M, Guerrero AD, Huang L, Shabier Z, Pan M, Tan TH et al. Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. J Biol Chem 2007; 282: 33888-33895.
21. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998; 95: 554-559.
22. Grandgirard D, Studer E, Monney L, Belser T, Fellay I, Borner C et al. Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 1998; 17: 1268-1278.
23. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H, Kulms D. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2011; 30: 575-587.
24. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116.
25. Dudgeon C,Wang P, Sun X, Peng R, Sun Q, Yu J et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol Cancer Ther 2010; 9: 2893-2902.
26. Shao RG, Shimizu T, Pommier Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp Cell Res 1997; 234: 388-397.
27. Ming L, Wang P, Bank A, Yu J, Zhang L. PUMA Dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells. J Biol Chem 2006; 281: 16034-16042.
28. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 2014; 15: 81-94.
29. Shawgo ME, Shelton SN, Robertson JD. Caspase-mediated Bak activation and cytochrome c release during intrinsic apoptotic cell death in Jurkat cells. J Biol Chem 2008; 283: 35532-35538.
30. Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C et al. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012; 287: 68-80.
31. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C et al. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One 2011; 6: e20586.
32. Peng X, Xie G, Wang Z, Lin H, Zhou T, Xiang P et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis 2014; 5: e1143.